Rithish (@RithishNim) header
Rithish (@RithishNim) profile picture

Assoc Editor-In-Chief @WikiDoc | PGY-2 @onebklynhealth | Former GI-Onco research Asst @MaimoHealth | GI cancers | @IMRC_Team | Bongos |

Brooklyn, NY
Joined March 2024
Photo by Rithish (@RithishNim)Photo by Rithish (@RithishNim)Photo by Rithish (@RithishNim)Photo by Rithish (@RithishNim)Photo by Rithish (@RithishNim)Photo by Rithish (@RithishNim)Photo by Rithish (@RithishNim)Photo by Rithish (@RithishNim)Photo by Rithish (@RithishNim)Photo by Rithish (@RithishNim)
Boom .!! OE or nothing
NEW: OpenEvidence just launched two free AI tools for clinicians. **Access Intelligence:** > 2,500+ patient assistance programs > Copay savings & enrollment > Prior auths and appeals **OpenEvidence Learn:** > 50,000+ board-style questions > AI-powered clinical case simulations > Flashcards & CME More AI for practicing and learning. Cool.
1
86
Rithish retweeted
Stopping GLP-1 treatment linked to twice the risk of heart attack, stroke or death compared with continuing, in people with type 2 diabetes and no cardiovascular disease, according to a new study. Find out more in @LancetRH_Europe: spkl.io/60137wUtS
62
246
92
804
380,476
Back to my comfort niche .! This time with some touch of sexual health with GI oncology our work has been accepted for poster presentation at the 2027 ASCO Gastrointestinal Cancers Symposium! 📍 San Francisco @ASCO #GICancers
1
119
Rithish retweeted
CART will never be widely available as long as transplanters pretend to “own” CART administration. CART is logistically harder than most therapies but not in the same ballpark as allo transplant. These therapies can be delivered in the community.
10
18
2
141
22,297
6 years ago, I had the chance to publish a paper that would end up changing my academic life It was a review article exploring the surprising activity of certain ADCs in “HER2-low” breast cancer, a newly emerging entity whose relevance was still uncertain. We tried to connect the dots, asking if HER2-low was a subtype vs just a target, wondering whether this concept could one day translate into meaningful benefits for patients. 6 years later, that article has reached 1,000 citations. My career has gifted me more than I could ever have imagined. More importantly, what was once an intriguing scientific observation has become a clinical reality: countless patients with HER2-low breast cancer now live longer thanks to T-DXd. A reminder of how far science can take us in just a few years. Grateful to everyone who has been part of this journey! ascopubs.org/doi/10.1200/JCO…
7
19
3
250
16,613
Glad to announce that our new paper has been published 😀 “Talquetamab and Its Effect on Relapsed and Refractory Multiple Myeloma” Grateful to all my co-authors for their contributions and collaboration in bringing this work to publication. #HemeOncology #MultipleMyeloma
1
149
Honored to have presented my work at the Lymphoma, Leukemia & Myeloma Congress! Grateful for the opportunity to share our research, learn from experts in the field @llmcongress #LLM2026 #Hematology #Oncology
5
164
⭐️Really loving the wording in the daraxonrasib FDA approval. Clear autonomy for physicians, centered on patient needs. 👉🏼“The approval is for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy” 👉🏼This is how oncology should move forward @OncoAlert @matthewherper @oncodaily @OpenEvidence @FDA @FDAOncology @FDAMedia @DrSamuelBHume
🚨🚨🚨⭐️HUGE news & a MAJOR milestone in oncology‼️ 👉🏼The FDA just approved the first targeted therapy for metastatic pancreatic cancer a breakthrough in precision oncology and a landmark step in making the BIG KRAS officially druggable ( beyond KRAS K12C) ❗️ $RVMD 👉🏼A new era in the fields battle against a devastating Emperor of all maladies. #precisionmedicine #KRAS @OncoAlert @oncodaily @DavidHongMD @Aiims1742 @DrShubhamPant @GIcancerDoc @EileenMOReilly fda.gov/news-events/press-an…
7
18
4
76
13,168
🚨 FDA APPROVAL | First-in-class RAS inhibitor in metastatic pancreatic cancer The FDA has approved Rasonque (daraxonrasib), an oral once-daily RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received ≥1 prior systemic therapy or are not candidates for multiagent systemic therapy. 📊 Randomized trial | N=500 • Median OS: 13.2 months • Standard chemotherapy: 6.7 months ➡️ Nearly doubling median overall survival in previously treated metastatic disease. ⚠️ Common adverse events included rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite and hemorrhage. 💡 Why it matters: RAS has long been one of the hardest oncogenic drivers to target. This approval introduces a new targeted treatment strategy into one of oncology’s highest-unmet-need diseases. Verdict: 🔥 Practice Changing @FDAOncology @OncoAlert #PancreaticCancer #Oncology #RAS #FDA
11
23
1,472
🚨🚨🔔🔔We have not one but two blood 🩸 tests FDA approved for CRC screening in average risk individuals in the US 👉🏼Implementation requires special attention, with focus on the unscreened 🧐 @NYULH_GastroHep @AmCollegeGastro
1
10
27
4,062
This time into books .! 📕
2
11
438
🚨 Excited to share our latest publication on ECMO anticoagulation! The ECMO landscape is shifting toward precision-based, individualized anticoagulation strategies that integrate In this review, we aimed to consolidate the evolving evidence into one comprehensive resource.
2
1
6
310
Another this week.! 1 year of patience and hustle finally paid off .! #Haematology
1
10
310
😅
🚨 New head-to-head RCT in @NEJM: apixaban vs rivaroxaban 🥊 🏆 Apixaban emerges as the safe winner, with half the risk of bleeding complications 💡 For patients at high risk of GI bleeding, apixaban may be preferrable to rivaroxaban nejm.org/doi/full/10.1056/NE…
24
343
13
2,287
277,198
Saindo do forno! 🔥 Apixabana ou rivaroxabana para tratar TEV agudo? Ambos são DOACs amplamente utilizados, mas nunca haviam sido comparados em um RCT. O estudo COBRRA (NEJM 2026) tentou responder uma pergunta clinicamente relevante: ➡️ Qual deles causa menos sangramento?
6
19
320
29,109
Such a welcoming and timely update to share during #CRCAwarenessMonth! Let’s continue raising awareness for colorectal cancer prevention and early detection. 💙 #Colorectalcarcinoma
1
1
4
173
ImmunoXXL Phase II Study: Liver Transplantation After Atezolizumab–Bevacizumab Downstaging in Advanced HCC In a prospective study, 16 patients with intermediate and advanced HCC beyond extended transplant criteria were downstaged with Atezo–Bev and underwent liver transplantation. Key outcomes • 2-year RFS: 90% • 2-year OS: 94% • Acute rejection: 25% The authors conclude that liver transplantation should be considered after HCC response to immunotherapy. @DJPinato @MariannaMaspero @MarcoBongini oncodaily.com/oncolibrary/im… #HCC #LiverCancer #Immunotherapy #TransplantOncology #Oncology
3
1
13
463